• Andrea Morotti, Gregoire Boulouis, Dar Dowlatshahi, Qi Li, Michel Shamy, Rustam Al-Shahi Salman, Jonathan Rosand, Charlotte Cordonnier, Joshua N Goldstein, and Andreas Charidimou.
• Neurology Unit, Department of Neurological Sciences and Vision, Azienda Socio Sanitaria Territoriale Spedali Civili, Brescia, Italy. Electronic address: andrea.morotti@ASST-spedalicivili.it.
• Lancet Neurol. 2023 Feb 1; 22 (2): 159171159-171.

AbstractHaematoma expansion affects a fifth of patients within 24 h of the onset of acute intracerebral haemorrhage and is associated with death and disability, which makes it an appealing therapeutic target. The time in which active intervention can be done is short as expansion occurs mostly within the first 3 h after onset. Baseline haemorrhage volume, antithrombotic treatment, and CT angiography spot signs are each associated with increased risk of haematoma expansion. Non-contrast CT features are promising predictors of haematoma expansion, but their potential contribution to current models is under investigation. Blood pressure lowering and haemostatic treatment minimise haematoma expansion but have not led to improved functional outcomes in randomised clinical trials. Ultra-early enrolment and selection of participants on the basis of non-contrast CT imaging markers could focus future clinical trials to show clinical benefit in people at high risk of expansion or investigate heterogeneity of treatment effects in clinical trials with broad inclusion criteria.Copyright © 2023 Elsevier Ltd. All rights reserved.

23 keywords...

hide…